Use of Vaccines for the Prevention of Typhoid Fever

Indian Pediatrics

Volumn 40, Issue 11, 2003, Pages 1029-1034

  Levine, Myron M ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; BUFFER; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; DEXAMETHASONE; LIVE VACCINE; POLIOMYELITIS VACCINE; POLYSACCHARIDE VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STEROID; TYPHOID VACCINE;

ACTIVE IMMUNIZATION; BACTERIAL INFECTION; BACTERIAL STRAIN; CLINICAL TRIAL; CONTAMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG PURIFICATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG SOLUBILITY; DRUG TOLERANCE; EDITORIAL; FREEZE DRYING; HEALTH PROGRAM; HUMAN; INFECTION PREVENTION; NONHUMAN; POPULATION RESEARCH; PREVENTIVE HEALTH SERVICE; RETICULOENDOTHELIAL SYSTEM; SALMONELLA ENTERICA; SALMONELLA TYPHI; SINGLE DRUG DOSE; TYPHOID FEVER;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; MALE; PRIMARY PREVENTION; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; VACCINATION; WORLD HEALTH;

EID: 0345686671     PISSN: 00196061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (25)

1. Gupta A. Multidrug-resistant typhoid fever in children: epidemiology and therapeutic approach. Pediatr Infect Dis 1994; 13: 124-140.
2. Mikhail IA, Haberberger RL, Farid Z, Girgis NI, Woody JN. Antibiotic-multiresistant Salmonella typhi in Egypt. Trans R Soc Trop Med Hyg 1989; 83: 120.
3. Wolman A, Gorman A. The significance of waterbome typhoid fever outbreaks. Baltimore: Williams & Wilkins, 1931; p 1-82.
4. Woodward TE, Smadel JE, Ley HL, Green R, Mankakan DS. Preliminary report on the beneficial effect of choloromycetin in the treatment of typhoid fever. Ann intern Med 1948; 29: 131-134.
5. Gilman RH, Terminel M, Levine MM, Hernandez Mendosa P, Calderone E, Vasquez V, et al. Comparison of trimethoprim-sulfamethoxazole and amoxicillin in therapy of chloramphenicol-resistant and chloramphenicol-sensitive typhoid fever. J Infect Dis 1975; 132: 630-636.
6. Butler T, Linh NN, Arnold K, Pollack M. Chloramphenicol-resistant typhoid fever in Vietnam associated with R factor. Lancet 1973; 2: 983-985.
7. Bavdekar A, Chaudhari M, Bhave S, Pandit A. Ciprofloxacin in typhoid fever. Indian J Pediatr 1991; 58: 335-339.
8. Wain J, Hoa NT, Chinh NT, Vinh H, Everett MJ, Diep TS, et al. Quinolone-resistant Salmonella typhi in Vietnam: Molecular basis of resistance and clinical response to treatment. Clin Infect Dis 1997; 25: 1404-1410.
9. Hoffman S, Punjabi N, Kumala S, et al. Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. N Engl J Med 1984; 310: 82-88.
10. Parkhill J, Dougan G, James KD, Thomson NR, Pickard D, Wain J, et al. Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CTI8. Nature 2001; 413 (6858): 848-852.
11. Levine, MM, Taylor DN, Ferreccio C. Typhoid vaccines come of age. Pediatr Infect Dis J 1989; 8: 374-381.
12. Levine MM, Ferreccio C, Black RE, Germanier R, Chilean Typhoid Committee. Large-scale field trial of Ty21 a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987; 1: 1049-1052.
13. Levine MM, Ferreccio C, Cryz S, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21 a typhoid vaccine in randomized controlled field trial. Lancet 1990; 336: 891-894.
14. Keitel W A, Bond N L, Zahradnik J M, Cramton T A, Robbins J B. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine 1994; 12: 195-199.
15. Levine MM, Ferreccio C, Abrego P, Martin OS, Ortiz E, Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 1999; 17 Suppl 2: S22-S27.
16. Levine MM, Ferreccio C, Black RE, Tacket CO, Germanier R. Progress in vaccines against typhoid fever. Rev Infect Dis 1989; 11 Suppl 3: S552-S567.
17. Ferreccio C, Levine MM, Rodriguez H, Contreras R. Comparative efficacy of two, three, or four doses of Ty21 alive oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J Infect Dis 1989; 159: 766-769.
18. Yang HH, Kilgore FE, Yang LH, Park JK, Pan YF, Kim Y, et al. An outbreak of typhoid fever, Xing-An County, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine. J Infect Dis 2001; 183: 1775-1780.
19. Tacket CO, Sztein MB, Wasserman SS, Losonsky G, Kotloff KL, Wyant TL, et al. Phase 2 clinical trial of attenuated Salmonella enterica serovar Typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect Immun 2000; 68: 1196-1201.
20. Hohmann EL, Oletta CA, Killeen KP, Miller SI. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J Infect Dis 1996; 173: 1408-1414.
21. Hindle Z, Chatfield SN, Phillimore J, Bentley M, Johnson J, Cosgrove CA, et al. Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect Immun 2002; 70: 3457-3467.
22. Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001; 344: 1263-1269.
23. Ferreccio C, Levine MM, Manterola A, Rodriguez G, Rivara I, Prenzel I, et al. Benign bacteremia caused by Salmonella typhi and paratyphi in children younger than 2 years. J Pediatr 1984; 104: 899-901.
24. Mahle WT, Levine MM. Salmonella typhi infection in children younger than five years of age. Pediatr Infect Dis J 1993; 12: 627-631.
25. Sinha A, Sazawal S, Kumar R, Sood S, Reddaiah VP, Singh B, et al. Typhoid fever in children aged less than 5 years. Lancet 1999; 354(9180): 734-737.